Michael R. Folkert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael R. Folkert has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
Brian Hrycushko
Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX
4 shared publicationsRobert D. Timmerman
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
3 shared publications- Robert Timmerman
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
3 shared publications Aaron M. Laine
Center for Cancer and Blood Disorders, Weatherford, Texas
2 shared publications- Alexandra K. Callan
Section of Musculoskeletal Oncology, Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
2 shared publications - Aurelie Garant
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
2 shared publications
Latest Publications
- 20 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (33) , 3213-3226
Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial
Purpose: Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification. Methods: F-SHARP is a multi-institutional phase I/II trial of DE-fsHDR for IPR after any form of RT for localized prostate cancer. Patients received up to 30 Gy in 1-2 fractions. The primary objective was to determine the acute RT-related grade ≥3 CTCAE v4.03 genitourinary and GI toxicity rates. Secondary end points included all-grade toxicity, quality of life (QoL; EPIC-26 and International Prostate Symptom Score), disease control, and survival. GC analysis used a clinical-grade transcriptome assay (Veracyte, San Diego, CA). Time-to-event outcomes included biochemical progression-free survival (bPFS), radiographic progression-free survival (rPFS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS). Results: Twenty-four participants received one fraction and 38 received two fractions (N = 62). The median follow-up was 39.4 months. No acute grade 3 toxicities occurred. Two patients (3.2%) had late grade 3 toxicity. QoL changes did not meet criteria for a minimal clinically important difference. Three-year survival rates were 62.7% (bPFS), 67.5% (rPFS), 73.0% (LRFS), and 85.9% (MFS); there were no differences between fractionation groups (all P > .05). Among 31 patients with GC results, higher scores were associated with worse bPFS, rPFS, LRFS, and MFS. All patients with GC score >0.85 (n = 4) experienced biochemical, local, and metastatic recurrence. Conclusion: DE-fsHDR is a safe and effective salvage treatment for IPR. GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.
- 20 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (33) , 3213-3226
Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial
Purpose: Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification. Methods: F-SHARP is a multi-institutional phase I/II trial of DE-fsHDR for IPR after any form of RT for localized prostate cancer. Patients received up to 30 Gy in 1-2 fractions. The primary objective was to determine the acute RT-related grade ≥3 CTCAE v4.03 genitourinary and GI toxicity rates. Secondary end points included all-grade toxicity, quality of life (QoL; EPIC-26 and International Prostate Symptom Score), disease control, and survival. GC analysis used a clinical-grade transcriptome assay (Veracyte, San Diego, CA). Time-to-event outcomes included biochemical progression-free survival (bPFS), radiographic progression-free survival (rPFS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS). Results: Twenty-four participants received one fraction and 38 received two fractions (N = 62). The median follow-up was 39.4 months. No acute grade 3 toxicities occurred. Two patients (3.2%) had late grade 3 toxicity. QoL changes did not meet criteria for a minimal clinically important difference. Three-year survival rates were 62.7% (bPFS), 67.5% (rPFS), 73.0% (LRFS), and 85.9% (MFS); there were no differences between fractionation groups (all P > .05). Among 31 patients with GC results, higher scores were associated with worse bPFS, rPFS, LRFS, and MFS. All patients with GC score >0.85 (n = 4) experienced biochemical, local, and metastatic recurrence. Conclusion: DE-fsHDR is a safe and effective salvage treatment for IPR. GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.
- 15 July 2026
- Published by Elsevier in Brachytherapy
- Vol. 25 (5) , 841-853
American Brachytherapy Society (ABS) competencies for endobronchial/esophageal brachytherapy
- 15 July 2026
- Published by Elsevier in Brachytherapy
- Vol. 25 (5) , 841-853
American Brachytherapy Society (ABS) competencies for endobronchial/esophageal brachytherapy
- Open Access
- 14 December 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (2) , 402-409
Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis
- 14 December 2025
- Published by Elsevier in Brachytherapy
- Vol. 25 (2) , 402-409
Open AccessAssociation between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis
- 1 November 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 7 (6) , e259030
Treatment-Response Prediction for Metastatic Castrate-Resistant Prostate Cancer Using PSMA PET
- 1 November 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 7 (6) , e259030
Treatment-Response Prediction for Metastatic Castrate-Resistant Prostate Cancer Using PSMA PET
- 23 September 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (6) , 833-843
American Brachytherapy Society (ABS) rectoprostatic gel spacer consensus statement
- 23 September 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (6) , 833-843
American Brachytherapy Society (ABS) rectoprostatic gel spacer consensus statement
- 2 July 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (5) , 631-643
Joint ABS/GEC-ESTRO Consensus Statement on the objectives of training in brachytherapy for physicians
- 2 July 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (5) , 631-643
Joint ABS/GEC-ESTRO Consensus Statement on the objectives of training in brachytherapy for physicians
- Open Access
- 7 June 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (12) , 101824
Real-World Medical Device Reports of SpaceOAR Hydrogel Spacer: Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) Database
- 7 June 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (12) , 101824
Open AccessReal-World Medical Device Reports of SpaceOAR Hydrogel Spacer: Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) Database
- 19 July 2023
- Published by Elsevier in Brachytherapy
- Vol. 22 (5) , 580-585
Organ sparing treatment for penile cancer using a 3D-printed high-dose-rate brachytherapy applicator
- 19 July 2023
- Published by Elsevier in Brachytherapy
- Vol. 22 (5) , 580-585
Organ sparing treatment for penile cancer using a 3D-printed high-dose-rate brachytherapy applicator
- Open Access
- 14 June 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (7)
Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study
Background & Aims: Early-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with ablation or SBRT in a multicenter, US cohort. Approach & Results: We included adult patients with treatment-naïve HCC lesions without vascular invasion treated with thermal ablation or SBRT per individual physician or institutional preference from January 2012 to December 2018. Outcomes included local progression after a 3-month landmark period assessed at the lesion level and overall survival at the patient level. Inverse probability of treatment weighting was used to account for imbalances in treatment groups. The Cox proportional hazard modeling was used to compare progression and overall survival, and logistic regression was used for toxicity. There were 642 patients with 786 lesions (median size: 2.1 cm) treated with ablation or SBRT. In adjusted analyses, SBRT was associated with a reduced risk of local progression compared to ablation (aHR 0.30, 95% CI: 0.15–0.60). However, SBRT-treated patients had an increased risk of liver dysfunction at 3 months (absolute difference 5.5%, aOR 2.31, 95% CI: 1.13–4.73) and death (aHR 2.04, 95% CI: 1.44–2.88, p < 0.0001). Conclusions: In this multicenter study of patients with HCC, SBRT was associated with a lower risk of local progression compared to thermal ablation but higher all-cause mortality. Survival differences may be attributable to residual confounding, patient selection, or downstream treatments. These retrospective real-world data help guide treatment decisions while demonstrating the need for a prospective clinical trial.
- 14 June 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (7)
Open AccessThermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study
Background & Aims: Early-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with ablation or SBRT in a multicenter, US cohort. Approach & Results: We included adult patients with treatment-naïve HCC lesions without vascular invasion treated with thermal ablation or SBRT per individual physician or institutional preference from January 2012 to December 2018. Outcomes included local progression after a 3-month landmark period assessed at the lesion level and overall survival at the patient level. Inverse probability of treatment weighting was used to account for imbalances in treatment groups. The Cox proportional hazard modeling was used to compare progression and overall survival, and logistic regression was used for toxicity. There were 642 patients with 786 lesions (median size: 2.1 cm) treated with ablation or SBRT. In adjusted analyses, SBRT was associated with a reduced risk of local progression compared to ablation (aHR 0.30, 95% CI: 0.15–0.60). However, SBRT-treated patients had an increased risk of liver dysfunction at 3 months (absolute difference 5.5%, aOR 2.31, 95% CI: 1.13–4.73) and death (aHR 2.04, 95% CI: 1.44–2.88, p < 0.0001). Conclusions: In this multicenter study of patients with HCC, SBRT was associated with a lower risk of local progression compared to thermal ablation but higher all-cause mortality. Survival differences may be attributable to residual confounding, patient selection, or downstream treatments. These retrospective real-world data help guide treatment decisions while demonstrating the need for a prospective clinical trial.
- Open Access
- 16 March 2023
- Published by Wolters Kluwer Health in OTA International
- Vol. 6 (2) , e267
Intramedullary brachytherapy for the treatment of long bone metastatic disease: A case report
Case: A 56-year-old woman with metastatic melanoma and femoral lesions with impending pathologic fracture was indicated for intramedullary brachytherapy (IMBT) and intramedullary nail. Conclusions: IMBT + intramedullary nail is a new technique for the treatment of long bone metastases. IMBT maximizes radiation to the tumor and minimizes radiation to surrounding tissues. It allows the patient to resume systemic treatment expediently. Our cadaver model and patient were both treated for femoral metastases; however, this technique allows for the treatment of any long bone. This is a safe technique that minimizes treatment time compared with other standard radiation regimens.
- 16 March 2023
- Published by Wolters Kluwer Health in OTA International
- Vol. 6 (2) , e267
Open AccessIntramedullary brachytherapy for the treatment of long bone metastatic disease: A case report
Case: A 56-year-old woman with metastatic melanoma and femoral lesions with impending pathologic fracture was indicated for intramedullary brachytherapy (IMBT) and intramedullary nail. Conclusions: IMBT + intramedullary nail is a new technique for the treatment of long bone metastases. IMBT maximizes radiation to the tumor and minimizes radiation to surrounding tissues. It allows the patient to resume systemic treatment expediently. Our cadaver model and patient were both treated for femoral metastases; however, this technique allows for the treatment of any long bone. This is a safe technique that minimizes treatment time compared with other standard radiation regimens.